This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A 2 Week Blinded Study For Pain Due To Arthritis Of The Knee

This study has been terminated.
(Met criteria for study futility at interim analysis)
Information provided by:
Pfizer Identifier:
First received: June 6, 2007
Last updated: April 22, 2011
Last verified: April 2011
The primary aim is to assess if PF-00592379 is able to reduce pain in patients with osteoarthritis of the knee.

Condition Intervention Phase
Osteoarthritis Drug: Oxycodone Drug: Placebo Drug: PF-000592379 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A 2 Week, Randomized, Double Blind, Placebo And Positive Controlled, Parallel Group, Multicentre Study To Assess The Efficacy And Tolerability Of PF-00592379 In Patients With Moderate To Severe Pain Due To Osteoarthritis

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change from baseline in the pain score averaged over the last week of treatment [ Time Frame: 2 weeks ]

Secondary Outcome Measures:
  • Western Ontario and McMaster University Osteoarthritis Index (WOMAC) pain score - change from baseline to end of treatment [ Time Frame: 2 weeks ]
  • Patient Global Impression of Change [ Time Frame: 2 weeks ]
  • Patients Global Assessment of Osteoarthritis [ Time Frame: 2 weeks ]
  • Pharmacokinetic trough levels [ Time Frame: 2 weeks ]

Enrollment: 113
Study Start Date: June 2007
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Oxycodone Drug: Oxycodone
Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
Placebo Comparator: Placebo Drug: Placebo
Placebo: oral for 2 weeks.
Experimental: PF-00592379 Drug: PF-000592379
PF-00592379: oral, 30 mg, once a day for 2 weeks


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female of any race
  • Between the ages of 18 and 75 years
  • Knee Pain due to osteoarthritis

Exclusion Criteria:

  • Pregnant
  • Participation in a clinical trial for an investigational drug and/or agent within 30 days prior to baseline
  • History of malignancy, convulsions, chronic infections, arthroscopy of the worst knee within the past year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00483977

United States, Alabama
Pfizer Investigational Site
Mobile, Alabama, United States, 36608
United States, Arizona
Pfizer Investigational Site
Tucson, Arizona, United States, 85741
United States, California
Pfizer Investigational Site
Carmichael, California, United States, 95608
Pfizer Investigational Site
Fair Oaks, California, United States, 95628
Pfizer Investigational Site
Orangevale, California, United States, 95662
Pfizer Investigational Site
Roseville, California, United States, 95661
Pfizer Investigational Site
Sacramento, California, United States, 95825
United States, Florida
Pfizer Investigational Site
Boca Raton, Florida, United States, 33486
Pfizer Investigational Site
DeLand, Florida, United States, 32720
Pfizer Investigational Site
Hollywood, Florida, United States, 33021
Pfizer Investigational Site
Longwood, Florida, United States, 32779
Pfizer Investigational Site
Miami, Florida, United States, 33186
United States, Kentucky
Pfizer Investigational Site
Louisville, Kentucky, United States, 40213
Pfizer Investigational Site
Madisonville, Kentucky, United States, 42431
United States, Missouri
Pfizer Investigational Site
St. Louis, Missouri, United States, 63141
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89146
United States, New York
Pfizer Investigational Site
New York, New York, United States, 10022-1009
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27704
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45227
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45242
United States, Virginia
Pfizer Investigational Site
Richmond, Virginia, United States, 23294
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trials Disclosure Group, Pfizer, Inc. Identifier: NCT00483977     History of Changes
Other Study ID Numbers: A7771010
Study First Received: June 6, 2007
Last Updated: April 22, 2011

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on August 18, 2017